SEOM–GEMCAD–TTD clinical guidelines for anal cancer (2025)

Clinical & Translational Oncology 2026 Open access

Read full text
Authors: Monica Guillot Morales, Ana Fernandez-Montes, Julen Fernández-Plana, Ismael Ghanem Cañete, M. Gil Raga, Jerónimo Jiménez-Castro, Ignacio Juez Martel, Joan Maurel, Eduardo Polo Marqués, María Auxiliadora Gómez‐España
DOI: 10.1007/s12094-025-04163-x
Cited by: 0

Abstract

Anal cancer is rare but increasingly common, currently accounting for 2% of all digestive neoplasms. Some 50% of anal cancers are diagnosed at the localized stage, 29% as locoregional disease, and 12% as metastatic disease. When clinical suspicion of anal cancer exists, histological confirmation, correct local staging with MRI and distant staging with thoraco-abdominal CT, and management by a multidisciplinary team are mandatory. Chemoradiotherapy with 5-FU and mitomycin C (MMC) is the standard of care for early and locally advanced disease, while combination chemotherapy with a platinum-containing compound and taxanes is the treatment of choice for metastatic disease.

Fields of Study & Subjects

Colorectal and Anal Carcinomas Colorectal Cancer Surgical Treatments Esophageal Cancer Research and Treatment

Publication details

Journal / source
Clinical & Translational Oncology
Volume
28
Issue
4
Pages
1138–1150
Publication date
7 February 2026
Language
EN